Science & Pipeline

At Imbria, we are translating our deep understanding of cardiac energy metabolism into novel cardiovascular disease treatments. Targeting cardiac energetics is a differentiated, foundational strategy to modify disease biology across multiple cardiovascular indications.

Our lead program, ninerafaxstat, is a novel investigational therapy designed to optimize mitochondrial energy production in heart muscle cells without adverse impact on left ventricular ejection fraction, heart rate, or blood pressure. In clinical trials to date, ninerafaxstat has shown compelling safety and efficacy potential in patients with nHCM, type 2 diabetes and obesity.